Conference Reports for NATAP

13th IAS Conference on HIV Science IAS 2026 July 26-31 Rio, Brazil Back

Once-Weekly Oral Islatravir/Lenacapavir (ISL/LEN) Versus Daily Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed Adults With HIV-1: Week 48 Results of the ISLEND-1 Phase 3 Trial       IAS 2026 Rio, Brazil